US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Aptose Biosciences, Inc. - Common Shares (NQ:APTO)

1.710 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptose Biosciences, Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024 ↗
APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Aptose Reports Results for the Second Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Announces Receipt of Deficiency Notice from Nasdaq
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Announces Results from Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Recap: Aptose Biosciences Q4 Earnings ↗
 
Via Benzinga
News headline image
Aptose Biosciences's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024 ↗
APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Aptose Reports Results for the First Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023 ↗
APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Aptose Reports Results for the Fourth Quarter and Full Year 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 26, 2024 ↗
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
News headline image
Levi Strauss Layoffs 2024: What to Know About the Latest LEVI Job Cuts ↗
Levi Strauss layoffs are coming for as much as 15% of its corporate workforce as it prepares for a rough economy in 2024! 
Via InvestorPlace
Topics Economy Workforce
News headline image
Why Is SU Group (SUGP) Stock Moving Today? ↗
SU Group stock volatile on Friday following the company's IPO earlier this week with shares currently trading below its debut price. 
Via InvestorPlace
Topics Initial Public Offering
News headline image
Why Is Aptose Biosciences (APTO) Stock Down Today? ↗
Aptose Biosciences stock is sliding lower on Friday as investors react to a public offering and private placement for APTO shares. 
Via InvestorPlace
News headline image
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket ↗
Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale. Tellurian shares jumped 16.3% to... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning! 
Via InvestorPlace
News headline image
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports Results for the Third Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients 
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >